CASC3 and plasma cell myeloma: This translates to improved survival in a well-defined in vivo murine myeloma model, and anti-MM potential was also consistently reproduced in primary MM samples isolated from fresh patient bone marrow biopsies, an activity that was synergistic with BTZ.